Does Narcolepsy Ever Go Away?

Narcolepsy can be a difficult condition to manage, with debilitating excessive daytime sleepiness and sudden weakness called cataplexy. So, it is natural to wonder about the long-term prognosis.

Woman sleeping at desk
South_agency / iStock

Though we are gradually gaining a better understanding of the disorder and ways to treat it, the question remains: Does narcolepsy ever go away?

Learn about the present theory of why narcolepsy occurs and whether the underlying cause can be reversed.

An Autoimmune Element

Narcolepsy is believed to be due to an autoimmune process. The immune system is responsible for fighting off infections, but sometimes this powerful arsenal is turned against the body itself.

When this occurs, specific syndromes may result, including hepatitis, rheumatoid arthritis, and even narcolepsy. There is growing evidence that an infection may trigger the body to react against itself in some individuals who are susceptible as a result of a genetic predisposition.

In narcolepsy, the body’s immune system begins to target and destroy a small population of neurons within the hypothalamus of the brain. These neurons, or nerve cells, contain a neurotransmitter called hypocretin or orexin.

As the disease evolves, the entire collection of 60,000 to 70,000 nerve cells in the hypothalamus are permanently destroyed. As a result, the level of hypocretin detected in the cerebrospinal fluid (CSF) that bathes the brain drops to zero.

This can be measured via a lumbar puncture. When patients have cataplexy, a type of weakness triggered by emotion, the hypocretin levels are usually zero and this characterizes type 1 narcolepsy.

Furthermore, this destructive autoimmune process may be provoked after infection (typically a cold or flu). More recently, an increased risk of narcolepsy was found following vaccination with Pandemrix, a monovalent H1N1 influenza vaccine produced for the 2009-2010 flu season and only used in Europe. Use has since been halted.

A Chronic Condition

Unfortunately, the destruction of these brain cells is typically complete and the resulting deficit is permanent. The damage that is done cannot presently be reversed. Therefore, narcolepsy is a chronic condition that requires persistent treatment.

There are multiple treatments that may be effective in treating the symptoms associated with narcolepsy. These may include stimulant medications, such as Provigil or Nuvigil, as well as medications that prevent cataplexy, such as Xyrem.

If you suffer from narcolepsy, it is important to speak with a sleep specialist who can tailor the treatment to your specific needs. Though disability often persists, some people are able to make adjustments with the use of medications to preserve many daily functions.

Hope remains in the years to come. New therapeutics may be able to prevent, slow, or reverse the destruction of these hypocretin-containing cells in susceptible individuals. Regeneration of this population of brain cells with stem cell transplants may also eventually be possible.

Though these interventions are still distant on the horizon, there remains the possibility that one day, narcolepsy may ultimately go away in those who are afflicted with it.

Was this page helpful?
Article Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Wozniak DR, Quinnell TG. Unmet needs of patients with narcolepsy: perspectives on emerging treatment optionsNat Sci Sleep. 2015;7:51–61. Published 2015 May 22. doi:10.2147/NSS.S56077

  2. Mahlios J, De la Herrán-Arita AK, Mignot E. The autoimmune basis of narcolepsyCurr Opin Neurobiol. 2013;23(5):767–773. doi:10.1016/j.conb.2013.04.013

  3. Smith DA, Germolec DR. Introduction to immunology and autoimmunityEnviron Health Perspect. 1999;107 Suppl 5(Suppl 5):661–665. doi:10.1289/ehp.99107s5661

  4. Arango MT, Shoenfeld Y, Cervera R, et al. Infection and autoimmune diseases. In: Anaya JM, Shoenfeld Y, Rojas-Villarraga A, et al., editors. Autoimmunity: From Bench to Bedside [Internet]. Bogota (Colombia): El Rosario University Press; 2013 Jul 18. Chapter 19. 

  5. Mahoney CE, Cogswell A, Koralnik IJ, Scammell TE. The neurobiological basis of narcolepsyNat Rev Neurosci. 2019;20(2):83–93. doi:10.1038/s41583-018-0097-x

  6. Ebrahim IO, Howard RS, Kopelman MD, Sharief MK, Williams AJ. The hypocretin/orexin systemJ R Soc Med. 2002;95(5):227–230. doi:10.1258/jrsm.95.5.227

  7. Heier MS, Evsiukova T, Vilming S, Gjerstad MD, Schrader H, Gautvik K. CSF hypocretin-1 levels and clinical profiles in narcolepsy and idiopathic CNS hypersomnia in NorwaySleep. 2007;30(8):969–973. doi:10.1093/sleep/30.8.969

  8. Schiappa C, Scarpelli S, D'Atri A, Gorgoni M, De Gennaro L. Narcolepsy and emotional experience: a review of the literatureBehav Brain Funct. 2018;14(1):19. Published 2018 Dec 26. doi:10.1186/s12993-018-0151-x

  9. Verstraeten T, Cohet C, Dos Santos G, et al. Pandemrix™ and narcolepsy: A critical appraisal of the observational studiesHum Vaccin Immunother. 2016;12(1):187–193. doi:10.1080/21645515.2015.1068486

  10. Akintomide GS, Rickards H. Narcolepsy: a reviewNeuropsychiatr Dis Treat. 2011;7:507–518. doi:10.2147/NDT.S23624

  11. Barateau L, Dauvilliers Y. Recent advances in treatment for narcolepsyTher Adv Neurol Disord. 2019;12:1756286419875622. Published 2019 Sep 26. doi:10.1177/1756286419875622

  12. Thorpy MJ, Hiller G. The Medical and Economic Burden of Narcolepsy: Implications for Managed CareAm Health Drug Benefits. 2017;10(5):233–241. PMID: 28975007

  13. Bhattarai J, Sumerall S. Current and Future Treatment Options for Narcolepsy: A ReviewSleep Sci. 2017;10(1):19–27. doi:10.5935/1984-0063.20170004

  14. Merkle FT, Maroof A, Wataya T, et al. Generation of neuropeptidergic hypothalamic neurons from human pluripotent stem cellsDevelopment. 2015;142(4):633–643. doi:10.1242/dev.117978

Additional Reading
  • Narcolepsy Fact Sheet. National Institute of Neurological Disorders and Stroke. Published August 16, 2019.

Related Articles